Latest news

Debiopharm granted European Orphan Drugs Status for Debio-0513 (PTR-262) for Myasthenia Gravis

Debiopharm and Salix pharmaceuticals sign license agreement for Sanvar®

Debiopharm applies for first europe marketing authorisation for Sanvar® in France

Debiopharm and Aurigene enter into an Agreement to identify and develop selective compounds for immuno-oncology targets

Moapar® 3-months approved for the lowering of testosterone to castrate serum levels for control of sexual drive in adult men

The Debiopharm Group and Sigma-Tau sign R&D and commercial agreement for Istaroxime in acute heart failure syndromes

The Debiopharm Group to initiate confirmatory phase III trial for Sanvar® in esophageal variceal bleeding

Debiopharm and TcLand sign R&D and exclusive license option for the development of sc28AT autoimmune diseases and transplantation

Debiopharm et la Haute Ecole Valaisanne collaborent pour développer les médicaments de demain